BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27100093)

  • 1. Diverse Basis of β-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis.
    Okabe H; Kinoshita H; Imai K; Nakagawa S; Higashi T; Arima K; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Ishiko T; Yoshizumi T; Beppu T; Monga SP; Baba H; Maehara Y
    PLoS One; 2016; 11(4):e0152695. PubMed ID: 27100093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.
    Lu LC; Shao YY; Lee YH; Hsieh MS; Hsiao CH; Lin HH; Kao HF; Ma YY; Yen FC; Cheng AL; Hsu CH
    Oncology; 2014; 87(3):159-66. PubMed ID: 25012536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and exon 3 mutation of beta-catenin in human hepatocellular carcinoma].
    Jiao Y; Ban KC; Cao J; Yue HY; Luo Y; Su JJ
    Ai Zheng; 2007 Oct; 26(10):1085-9. PubMed ID: 17927878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
    Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
    Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
    J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
    Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
    Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1.
    Devereux TR; Stern MC; Flake GP; Yu MC; Zhang ZQ; London SJ; Taylor JA
    Mol Carcinog; 2001 Jun; 31(2):68-73. PubMed ID: 11429783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
    Cieply B; Zeng G; Proverbs-Singh T; Geller DA; Monga SP
    Hepatology; 2009 Mar; 49(3):821-31. PubMed ID: 19101982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
    Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
    Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Longerich T; Endris V; Neumann O; Rempel E; Kirchner M; Abadi Z; Uhrig S; Kriegsmann M; Weiss KH; Breuhahn K; Mehrabi A; Weber TF; Wilkens L; Straub BK; Rosenwald A; Schulze F; Brors B; Froehling S; Pellegrino R; Budczies J; Schirmacher P; Stenzinger A
    Gut; 2019 Jul; 68(7):1287-1296. PubMed ID: 30901310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.
    Audard V; Grimber G; Elie C; Radenen B; Audebourg A; Letourneur F; Soubrane O; Vacher-Lavenu MC; Perret C; Cavard C; Terris B
    J Pathol; 2007 Jul; 212(3):345-52. PubMed ID: 17487939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
    Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
    J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability.
    Ueda Y; Hiyama E; Kamimatsuse A; Kamei N; Ogura K; Sueda T
    J Pediatr Surg; 2011 Dec; 46(12):2221-7. PubMed ID: 22152854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
    Ishizaki Y; Ikeda S; Fujimori M; Shimizu Y; Kurihara T; Itamoto T; Kikuchi A; Okajima M; Asahara T
    Int J Oncol; 2004 May; 24(5):1077-83. PubMed ID: 15067328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.